The tethered agonist approach to mapping ion channel proteins toward a structural model for the agonist binding site of the nicotinic acetylcholine receptor
Lt. Li et al., The tethered agonist approach to mapping ion channel proteins toward a structural model for the agonist binding site of the nicotinic acetylcholine receptor, CHEM BIOL, 8(1), 2001, pp. 47-58
Background: The integral membrane proteins of neurons and other excitable c
ells are generally resistant to high resolution structural tools. Structure
-function studies, especially those enhanced by the nonsense suppression me
thodology for unnatural amino acid incorporation, constitute one of the mos
t powerful probes of ion channels and related structures. The nonsense supp
ression methodology can also be used to incorporate functional side chains
designed to deliver novel structural probes to membrane proteins. In this v
ein, we sought to generalize a potentially powerful tool - the tethered ago
nist approach - for mapping the agonist binding site of ligand-gated ion ch
annels.
Results: Using the in vivo nonsense suppression method for unnatural amino
acid incorporation, a series of tethered quaternary ammonium derivatives of
tyrosine have been incorporated into the nicotinic acetylcholine receptor.
At three sites a constitutively active receptor results, but the pattern o
f activation as a function of chain length is different. At position alpha
149, there is a clear preference for a three-carbon tether, while at positi
on alpha 93 tethers of 2-5 carbons are comparably effective. At position ga
mma 55/delta 57 all tethers except the shortest one call activate the recep
tor. Based on these and other data, a model for the receptor binding site c
an be developed by analogy to the acetylcholine esterase crystal structure.
Conclusion: Through thr: use of nonsense suppression techniques, the tether
ed agonist approach has been made into a general tool for probing receptor
structures. When applied to the nicotinic receptor. the method places neu r
estrictions on developing models For the agonist binding site. (C) 2001 Els
evier Science Ltd. All rights reserved.